⌕
Immix Biopharma · IMMX · Nasdaq
Tenet 69 · Solid
Compare
$7.48−4.59%At closeTenet 69 · Solid
$7.48−0.36 (−4.59%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Immix Biopharma (IMMX) Stock

Immix Biopharma (IMMX) closed at $7.48 on Nov 16, 2026; its Tenet Score is 69 of 100 against 409 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

Key stats

Previous close
$7.48
Nov 16, 2026
Market cap
$626.9M
share price × the latest quarter's diluted weighted-average share count (vendor)
Dividend yield
0.00%
reinvests all
52-week range
3.45 – 15.10
low → high
Tenet Score
69/100
Solid · 409 Healthcare peers

Industry: Drugs · see every company filed here →

Immix Biopharma Inc scores 69/100. Solid. Strongest on financial health and value, quality is the soft spot versus 409 Healthcare peers. Insufficient inputs: Tenet 69 is built from 3 of 4 pillars, from 35% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=409
69/ 100
Solid
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
79
Quality
36
Health
90
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
ValueBQualityDHealthAGrowth—MomentumA+
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
2.0×
cap ÷ Sep 30, 2026 book value, Nov 13, 2026 close
P/S
—
no P/S on file
ROE
−27%
TTM through Sep 30, 2026
Operating margin
—
no operating margin on file
Net margin
—
Not reported in the company's filings for this period.
Current ratio
33.72
Sep 30, 2026 balance sheet
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 1y
—
This growth figure starts in a period outside the history your plan includes.

The whole report, at a glance · every card is a live peek, click any to open the section

About Immix Biopharma Inc

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=409) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 37 US ETFs · top wrappers by weightSee all ETFs holding IMMX →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Immix Biopharma in?

Immix Biopharma is in the Healthcare sector and the Drugs industry.

What is Immix Biopharma's Tenet Score?

Immix Biopharma's Tenet Score is 69 out of 100, ranked against 409 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.